ea0014oc1.4 | Thyroid clinical | ECE2007
Mannavola Deborah
, Vannucchi Guia
, Carletto Marco
, Longari Virgilio
, Bertuelli Rossella
, Coco Paola
, Casali Paolo
, Beck-Peccoz Paolo
, Fugazzola Laura
Sunitinib (SU11248) is a multitarget inhibitor of tyrosine-kinases (RTK) recently tested in clinical trials for the treatment of some human cancers. Side effects are mostly represented by asthenia and appear in a dose and time correlated manner. After the unexpected observation of a myxedematous coma in a patient affected with GIST and treated with Sunitinib, we evaluated the effect of this drug on thyroid function in 24 patients treated for GISTs Imatinib resistant. Patients ...